Ciaran Kohli-Lynch
@ceed.bsky.social
Health Economist @ Northwestern Med.
All views my own.
All views my own.
Reposted by Ciaran Kohli-Lynch
The biggest issue in NYC for the last few years, BY FAR, has been cost of living, and the candidate who won focuses his entire campaign messaging on that issue.
June 25, 2025 at 3:27 AM
The biggest issue in NYC for the last few years, BY FAR, has been cost of living, and the candidate who won focuses his entire campaign messaging on that issue.
As the Editor’s Note on our article stated: “The next step toward health equity in the US? Approve and implement a CVD polypill.” jamanetwork.com/journals/jam...
Genius and the CVD Polypill—A Step Toward Achieving Health Equity?
Over 2 decades ago, the idea for a polypill emerged as a plausible solution to reduce the global burden of cardiovascular disease (CVD) in low- and middle-income countries.1 Although with imperfect im...
jamanetwork.com
January 22, 2025 at 6:51 PM
As the Editor’s Note on our article stated: “The next step toward health equity in the US? Approve and implement a CVD polypill.” jamanetwork.com/journals/jam...
What next?
Despite evidence supporting the cost-effectiveness of polypills, no manufacturer has invested the millions of $$$ required to gain FDA approval. Hopefully, this study will signal demand for the cardiovascular polypill to policymakers and manufacturers.
Despite evidence supporting the cost-effectiveness of polypills, no manufacturer has invested the millions of $$$ required to gain FDA approval. Hopefully, this study will signal demand for the cardiovascular polypill to policymakers and manufacturers.
January 22, 2025 at 6:51 PM
What next?
Despite evidence supporting the cost-effectiveness of polypills, no manufacturer has invested the millions of $$$ required to gain FDA approval. Hopefully, this study will signal demand for the cardiovascular polypill to policymakers and manufacturers.
Despite evidence supporting the cost-effectiveness of polypills, no manufacturer has invested the millions of $$$ required to gain FDA approval. Hopefully, this study will signal demand for the cardiovascular polypill to policymakers and manufacturers.
For all trial-eligible non-Hispanic Black adults, polypill treatment was high value ($13,400-per-QALY gained).
It also yielded more QALYs and lower ICERs among poorer individuals, suggesting the polypill could cost-effectively reduce income-related health inequalities.
It also yielded more QALYs and lower ICERs among poorer individuals, suggesting the polypill could cost-effectively reduce income-related health inequalities.
January 22, 2025 at 6:51 PM
For all trial-eligible non-Hispanic Black adults, polypill treatment was high value ($13,400-per-QALY gained).
It also yielded more QALYs and lower ICERs among poorer individuals, suggesting the polypill could cost-effectively reduce income-related health inequalities.
It also yielded more QALYs and lower ICERs among poorer individuals, suggesting the polypill could cost-effectively reduce income-related health inequalities.
The polypill would lead to a net reduction in healthcare costs at annual prices below $443, and would remain high value at prices below $559.
January 22, 2025 at 6:51 PM
The polypill would lead to a net reduction in healthcare costs at annual prices below $443, and would remain high value at prices below $559.
Findings!
For a trial-representative cohort of 100,000 individuals, compared to usual care, polypill treatment:
- prevented 2,738 CVD events
- yielded 1,190 QALYs
- increased costs by ~$10,152,000
Hence, polypill treatment cost $8,560-per-QALY gained and was high value.
For a trial-representative cohort of 100,000 individuals, compared to usual care, polypill treatment:
- prevented 2,738 CVD events
- yielded 1,190 QALYs
- increased costs by ~$10,152,000
Hence, polypill treatment cost $8,560-per-QALY gained and was high value.
January 22, 2025 at 6:51 PM
Findings!
For a trial-representative cohort of 100,000 individuals, compared to usual care, polypill treatment:
- prevented 2,738 CVD events
- yielded 1,190 QALYs
- increased costs by ~$10,152,000
Hence, polypill treatment cost $8,560-per-QALY gained and was high value.
For a trial-representative cohort of 100,000 individuals, compared to usual care, polypill treatment:
- prevented 2,738 CVD events
- yielded 1,190 QALYs
- increased costs by ~$10,152,000
Hence, polypill treatment cost $8,560-per-QALY gained and was high value.
In the base case, we assumed an annual polypill price of $463: the combined median price of 3 half-standard dose BP-reducing medications and intermediate-intensity statin therapy.
January 22, 2025 at 6:51 PM
In the base case, we assumed an annual polypill price of $463: the combined median price of 3 half-standard dose BP-reducing medications and intermediate-intensity statin therapy.